Skip to main content

Troubled Zymergen renegotiates loan, cuts 100 more jobs and loses co-founder

The moves are in line with acting CEO Jay Flatley's plans to cut costs at the East Bay synthetic biology company, which just six months ago was a Wall Street darling with a $575 million IPO.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.